Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents

P. Larochelle, C. Kollmannsberger, R. D. Feldman, E. L. Schiffrin, L. Poirier, F. Patenaude, D. Ruether, M. Myers, G. Bjarnason


Inhibitors of the vascular endothelial growth factor (VEGF-IS) signalling pathway have fundamentally changed the treatment of metastatic renal cell carcinoma (MRCC). Hypertension is one of the most common side effects of VEGF-IS and has been reported with almost every VEGF-I used for treatment to date. The exact mechanism of VEGF-I–induced hypertension appears complex and multifactorial, and it remains to be fully explained. No randomized clinical trials are available to guide the management of hypertension during VEGF-I treatment in MRCC patients. The guiding principles suggested here summarize the consensus of opinions on the diagnosis and management of VEGF-I–induced hypertension during treatment of MRCC obtained from an expert working group composed of 4 Canadian medical oncologists and 5 Canadian hypertension specialists. The Canadian Hypertension Education Program guidelines, available literature, and expert opinion were used to develop the guiding principles.

Full Text:


DOI: http://dx.doi.org/10.3747/co.19.972

Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)